Literature DB >> 9808334

Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism.

A Ishikawa1, H Takahashi.   

Abstract

The onset of autosomal recessive-type parkinsonism is usually at a relatively young age (i.e. before the age of 40 years) and is thus called autosomal recessive juvenile parkinsonism (AR-JP). Here the clinical features, laboratory and imaging findings, neuropathological features, differential diagnosis and treatment options of AR-JP are described. We have treated 17 patients with AR-JP; they presented with sleep benefit in parkinsonian symptoms and foot dystonia as specific signs. The parkinsonian triad was mild, and the tremor was usually fine postural. A postural instability and adiadochokinesia were rather prominent. Gait freezing and hyperreflexia were frequently observed. The levodopa efficacy was sufficient and the clinical course was benign; however, choreic limb dyskinesia and the wearing-off phenomenon occurred easily. A neuropathological examination of one of the patients revealed that in the substantia nigra pars compacta and locus ceruleus, the number of neurons was low, and the content of neuromelanin in the neurons was small. There were focal degenerations (e.g. gliosis and extraneuronal free melanin) in the substantia nigra pars compacta. In addition, Lewy bodies were not found anywhere in the central nervous system. Considering these specific clinical and neuropathological findings, AR-JP seems to constitute one disease entity.

Entities:  

Mesh:

Year:  1998        PMID: 9808334     DOI: 10.1007/pl00007745

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  17 in total

1.  The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval.

Authors:  Alexander Zimprich; Bertram Müller-Myhsok; Matthew Farrer; Petra Leitner; Manu Sharma; Mary Hulihan; Paul Lockhart; Audrey Strongosky; Jennifer Kachergus; Donald B Calne; Jon Stoessl; Ryan J Uitti; Ronald F Pfeiffer; Claudia Trenkwalder; Nikolaus Homann; Erwin Ott; Karoline Wenzel; Friedrich Asmus; John Hardy; Zbigniew Wszolek; Thomas Gasser
Journal:  Am J Hum Genet       Date:  2003-12-19       Impact factor: 11.025

Review 2.  The role of parkin in familial and sporadic Parkinson's disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

3.  A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics.

Authors:  Mario R Cornejo-Olivas; Luis Torres; Ignacio F Mata; Pilar Mazzetti; Diana Rivas; Carlos Cosentino; Miguel Inca-Martinez; Juan M Cuba; Cyrus P Zabetian; James B Leverenz
Journal:  Parkinsonism Relat Disord       Date:  2015-01-15       Impact factor: 4.891

Review 4.  Melanin affinity and its possible role in neurodegeneration.

Authors:  Oskar Karlsson; Nils Gunnar Lindquist
Journal:  J Neural Transm (Vienna)       Date:  2013-07-03       Impact factor: 3.575

5.  Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1.

Authors:  Y Zhang; J Gao; K K Chung; H Huang; V L Dawson; T M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

Review 6.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

Review 7.  Chasing genes in Alzheimer's and Parkinson's disease.

Authors:  Aida M Bertoli-Avella; Ben A Oostra; Peter Heutink
Journal:  Hum Genet       Date:  2004-03-04       Impact factor: 4.132

8.  Neuromelanin is an immune stimulator for dendritic cells in vitro.

Authors:  Uwe Oberländer; Katrien Pletinckx; Anja Döhler; Nora Müller; Manfred B Lutz; Thomas Arzberger; Peter Riederer; Manfred Gerlach; Eleni Koutsilieri; Carsten Scheller
Journal:  BMC Neurosci       Date:  2011-11-15       Impact factor: 3.288

9.  Neuromelanin activates proinflammatory microglia through a caspase-8-dependent mechanism.

Authors:  Nikenza Viceconte; Miguel A Burguillos; Antonio J Herrera; Rocío M De Pablos; Bertrand Joseph; José L Venero
Journal:  J Neuroinflammation       Date:  2015-01-14       Impact factor: 8.322

10.  Role of oxidative stress in Parkinson's disease.

Authors:  Onyou Hwang
Journal:  Exp Neurobiol       Date:  2013-03-31       Impact factor: 3.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.